Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. more
Time Frame | ESLA | Sector | S&P500 |
---|---|---|---|
1-Week Return | 7.49% | -1.57% | 0.94% |
1-Month Return | 43.53% | -1.86% | 5.38% |
3-Month Return | 15.09% | -6.07% | 10.61% |
6-Month Return | 31.18% | -0.47% | 13.65% |
1-Year Return | -4.69% | 10% | 33.13% |
3-Year Return | -87.71% | 10.67% | 32.44% |
5-Year Return | -87.49% | 45.46% | 94.89% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Cost of Revenue | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Profit | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Gross Margin | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Operating Expenses | 733.69K | 1.69M | 1.57M | 7.31M | [{"date":"2020-12-31","value":10.04,"profit":true},{"date":"2021-12-31","value":23.06,"profit":true},{"date":"2022-12-31","value":21.47,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (733.69K) | (1.69M) | (1.57M) | (7.31M) | [{"date":"2020-12-31","value":-73369300,"profit":false},{"date":"2021-12-31","value":-168534700,"profit":false},{"date":"2022-12-31","value":-156953000,"profit":false},{"date":"2023-12-31","value":-731009800,"profit":false}] | |
Total Non-Operating Income/Expense | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Pre-Tax Income | (733.69K) | (1.69M) | (915.46K) | (7.31M) | [{"date":"2020-12-31","value":-73369300,"profit":false},{"date":"2021-12-31","value":-168534700,"profit":false},{"date":"2022-12-31","value":-91545600,"profit":false},{"date":"2023-12-31","value":-731009800,"profit":false}] | |
Income Taxes | (206.30K) | (235.14K) | 80.65K | - | [{"date":"2020-12-31","value":-255.8,"profit":false},{"date":"2021-12-31","value":-291.56,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income After Taxes | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Income From Continuous Operations | (733.69K) | (1.69M) | (6.88M) | (7.31M) | [{"date":"2020-12-31","value":-73369300,"profit":false},{"date":"2021-12-31","value":-168534700,"profit":false},{"date":"2022-12-31","value":-688422700,"profit":false},{"date":"2023-12-31","value":-731172300,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (733.69K) | (1.69M) | (996.10K) | (7.31M) | [{"date":"2020-12-31","value":-73369300,"profit":false},{"date":"2021-12-31","value":-168534700,"profit":false},{"date":"2022-12-31","value":-99610400,"profit":false},{"date":"2023-12-31","value":-731172300,"profit":false}] | |
EPS (Diluted) | - | (0.14) | (0.25) | (1.87) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-14,"profit":false},{"date":"2022-12-31","value":-25,"profit":false},{"date":"2023-12-31","value":-186.57,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
ESLA | |
---|---|
Cash Ratio | 0.60 |
Current Ratio | 0.75 |
Quick Ratio | 0.84 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ESLA | |
---|---|
ROA (LTM) | -122.12% |
ROE (LTM) | -278.12% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ESLA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.80 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.20 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ESLA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 58.17 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Estrella Immunopharma Inc. (ESLA) share price today is $1.22
Yes, Indians can buy shares of Estrella Immunopharma Inc. (ESLA) on Vested. To buy Estrella Immunopharma Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ESLA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Estrella Immunopharma Inc. (ESLA) via the Vested app. You can start investing in Estrella Immunopharma Inc. (ESLA) with a minimum investment of $1.
You can invest in shares of Estrella Immunopharma Inc. (ESLA) via Vested in three simple steps:
The 52-week high price of Estrella Immunopharma Inc. (ESLA) is $3.23. The 52-week low price of Estrella Immunopharma Inc. (ESLA) is $0.63.
The price-to-earnings (P/E) ratio of Estrella Immunopharma Inc. (ESLA) is
The price-to-book (P/B) ratio of Estrella Immunopharma Inc. (ESLA) is 58.17
The dividend yield of Estrella Immunopharma Inc. (ESLA) is 0.00%
The market capitalization of Estrella Immunopharma Inc. (ESLA) is $43.41M
The stock symbol (or ticker) of Estrella Immunopharma Inc. is ESLA